Navigation Links
Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
Date:12/1/2011

h edema and occasionally serious fluid retention. Patients should be weighed and monitored regularly for signs and symptoms of fluid retention, which can be serious or life-threatening. Be advised to carefully investigate and provide appropriate management for unexpected weight gain. The probability of edema tended to be increased among older patients (>65 years) or those taking higher doses of GLEEVEC. If severe fluid retention occurs, GLEEVEC should be withheld until the event has resolved and then resumed depending on the initial severity of the event.

Cytopenias have been reported. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months). Dose reduction or treatment interruption may be required for severe neutropenia or thrombocytopenia (see full Prescribing Information for dose adjustment recommendations).

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of GLEEVEC. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment. If severe hepatotoxicity occurs, GLEEVEC should be withheld
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
2. Genentech and Novartis Remain Image Leaders in Oncology and Hematology
3. FDA Advisory Committee Recommends US Approval of Novartis Once-daily Bronchodilator QAB149 for COPD
4. Novartis Drug Afinitor® Extends Progression-Free Survival in Patients With Advanced Pancreatic NET, Study Published in NEJM Shows
5. With the Recent Launch of Novartiss Gilenya, Extavia is Pushed Into the Background of Multiple Sclerosis Treatment One Year After its Launch
6. VIDEO from Novartis Available on thenewsmarket.com: Novartis Presents Data about Tasigna in Treatment of Patients with Newly Diagnosed Ph+ Chronic Myeloid Leukemia
7. Drug Sales in the Leukemia Market Will Be Driven By Therapies From Novartis, Bristol-Myers Squibb, Biogen Idec, Roche and Cephalon
8. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
9. Novartis Class Awarded $250 Million in Punitive Damages
10. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
11. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 This is a professional ... China Isopropanol (IPA) industry. The report provides a ... and industry chain structure. Global market analysis and ... focus on history, developments, trends and competitive landscape ... and Chinese situation is also offered. , The ...
(Date:9/23/2014)... 23, 2014 Equashield ( ...     Devices  (CSTD) for hazardous drugs, ... Medical Technology Corporation.  Equashield,s leading CSTD has been ... , China and ... to expand globally, and throughout the ...
(Date:9/23/2014)... Dr. Williams says, “Find The Black Box ( ... three phase process that can lead to the creation ... go far beyond anything previously imagined. First everyone must ... , “Every effort to improve the quality of healthcare ... throughout that system because all of the experts have ...
(Date:9/23/2014)... , September 23, 2014 ... with funding from Imperial Innovations, Cambridge Innovation Capital and ... a clinical cancer genomics company focused on harnessing ... to improve cancer testing and treatment, today announced ... led by Imperial Innovations and including Cambridge Innovation ...
Breaking Biology Technology:(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 2(IPA) Isopropanol Industry International & China Development Trend Analysis Now Available at DeepResearchReports.com 3Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Dr. Ira Williams Offers the Healthcare Solution Necessary for Patient Safety Improvement 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4
... Austria, May 27 The atherosclerosis vaccine,development program ... the,EU,s EUROTRANS-BIO call. The respective project is being ... GmbH. The aim of,atherosclerosis vaccination is to increase ... in the blood and thus reduce the occurrence ...
... Efficiency and Manage Quality at New LIFE Nutrition Factory ... (NYSE: HON ) today announced that it ... manufacturer of healthcare products, to provide process control solutions ... and infusion therapy solutions. The Leading Infusion Factory Europe ...
... SEATTLE, May 27 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ... previously announced sale of 3,878,993 shares of its common stock ... for gross proceeds of approximately $11.1 million on May 26, ... unit (each unit consisting of one share and a warrant ...
Cached Biology Technology:AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 2AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 2Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 3Honeywell to Help B. Braun Healthcare Company Double Manufacturing Capacity of Life-Critical Products 4Oncothyreon announces closing of $11.1 million registered direct financing 2
(Date:9/23/2014)... consumption could be as good for your mental as ... conducted by the University of Warwick,s Medical School using ... by BMJ Open focused on mental wellbeing ... consistently associated with an individual,s fruit and vegetable consumption. ... five or more portions of fruit and vegetables a ...
(Date:9/23/2014)... including humans, have parasitic DNA fragments called "jumping genes" ... in the process. And that phenomenon can result in ... University of Rochester now report that the "jumping genes" ... a multi-function protein stops keeping them in check in ... a study published today in Nature Communications , ...
(Date:9/22/2014)... STATION The smell of cut grass in recent ... signalling distress, but new research says the aroma also ... is need for protection, the plant signals the environment ... recognized as a feeding queue for parasitic wasps to ... lay eggs in the pest insect," said Dr. Michael ...
Breaking Biology News(10 mins):Eating five a day may keep the blues away 2A multi-function protein is key to stopping genomic parasites from 'jumping' 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 2Mown grass smell sends SOS for help in resisting insect attacks, researchers say 3
... This release is available in Spanish . ... Medical Research (CIMA) of the University of Navarra has identified ... enzyme is involved in the accumulation of fibrous tissues in ... of heart functions. The research project, published in the ...
... April 21 More than 3,200 items of ... be displayed during the 2009 Force Protection Equipment ... VA, and Marine Corps Base, Quantico, VA, during ... of Defense, personnel with physical security responsibilities in ...
... losses and the environmental impact caused by invasive species ... alone. An example of this is the zebra mussel, ... to a New York Sea Grant report. In ... species, the armored catfish, or plecostomus, in the Infiernillo ...
Cached Biology News:Researchers identify a molecule that increases the risk of cardiac insufficiency 2Combating Terrorism with Commercial Technology: 2009 Force Protection Equipment Demonstration 2North America works to halt invasive species 2
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
...
All serum is collected from U.S.D.A. fryers and broilers. Pricing: $15/unit for 1 - 10 units; $12/unit for 11 - 50 units...
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
Biology Products: